
In a study, ertugliflozin was found to significantly lower uric acid (UA) levels compared to placebo in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Over 260 weeks, mean UA decreased by 0.19 mg/dL with ertugliflozin versus a 0.07 mg/dL increase with placebo, resulting in a placebo-adjusted reduction of 0.26 mg/dL (P < 0.001). Ertugliflozin also reduced the incidence of gout-related outcomes, with 2.6% of patients experiencing such events compared to 3.3% in the placebo group (hazard ratio 0.76; 95% CI, 0.58–1.00). These findings suggest that ertugliflozin not only lowers UA levels but may also reduce the risk of gout in this patient population.
Like
Save
Share